Rapid health technology assessment of dapagliflozin in the treatment of type 2 diabetes mellitus combined with cardiovascular disease
- VernacularTitle:达格列净治疗2型糖尿病合并心血管疾病的快速卫生技术评估
- Author:
Huimin PAN
1
,
2
;
Yubo WANG
1
,
2
;
Ji CHEN
1
,
2
;
Huiting SHAN
1
,
2
;
Chunyan CHEN
1
,
2
;
Jianhua YANG
1
Author Information
1. Dept. of Pharmacy，the First Affiliated Hospital of Xinjiang Medical University，Urumqi 830011，China
2. Xinjiang Key Laboratory of Clinical Drug Research，Urumqi 830011，China
- Publication Type:Journal Article
- Keywords:
dapagliflozin;
type 2 diabetes mellitus
- From:
China Pharmacy
2024;35(18):2293-2298
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the safety， efficacy and economics of dapagliflozin in the treatment of type 2 diabetes mellitus （T2DM） combined with cardiovascular disease （CVD）， and provide an evidence-based basis for clinical treatment decisions. METHODS PubMed， the Cochrane Library， Embase， Web of Science， CNKI， Wanfang data， VIP， SinoMed and official websites of domestic and foreign health technology assessment （HTA） organizations were systematically searched. HTA reports， systematic evaluations/meta-analyses， and pharmacoeconomic studies of dapagliflozin in the treatment of T2DM combined with CVD were searched. After data extraction and quality assessment， the results of the included studies were analyzed descriptively. RESULTS A total of 13 papers were included， of which 10 were systematic evaluations/meta-analyses and 3 were pharmacoeconomic studies. In terms of efficacy， dapagliflozin significantly reduced patients’ glycosylated hemoglobin， body weight， body mass index and blood pressure levels compared with placebo， without increasing the risk of all-cause mortality； in terms of safety， dapagliflozin did not increase the risk of overall adverse events， major adverse cardiovascular events， cardiovascular death， hospitalization for heart failure， myocardial infarction， stroke， bone fracture and renal hypoplasia； in terms of economics， the UK and Chinese studies found an economic advantage for dapagliflozin， the Thai study did not. CONCLUSIONS Dagliflozin has better efficacy and safety in the treatment of T2DM combined with CVD， and its economic findings are still controversial in different countries， with economic advantages in the context of current Chinese healthcare policies and drug prices.
